Insmed Inc (INSM)
24.36
-0.44
(-1.75%)
USD |
NASDAQ |
Apr 19, 16:00
24.36
0.00 (0.00%)
After-Hours: 16:22
Insmed Cash from Financing (TTM): 168.44M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 168.44M |
September 30, 2023 | 788.56M |
June 30, 2023 | 824.43M |
March 31, 2023 | 786.42M |
December 31, 2022 | 793.27M |
September 30, 2022 | 55.60M |
June 30, 2022 | 21.02M |
March 31, 2022 | 612.30M |
December 31, 2021 | 612.55M |
September 30, 2021 | 618.85M |
June 30, 2021 | 622.41M |
March 31, 2021 | 275.57M |
December 31, 2020 | 271.00M |
September 30, 2020 | 268.23M |
June 30, 2020 | 263.49M |
March 31, 2020 | 284.36M |
December 31, 2019 | 285.28M |
September 30, 2019 | 278.46M |
June 30, 2019 | 277.71M |
March 31, 2019 | 11.63M |
December 31, 2018 | 386.74M |
September 30, 2018 | 384.75M |
June 30, 2018 | 762.37M |
March 31, 2018 | 758.69M |
December 31, 2017 | 381.09M |
Date | Value |
---|---|
September 30, 2017 | 401.51M |
June 30, 2017 | 32.98M |
March 31, 2017 | 31.16M |
December 31, 2016 | 30.67M |
September 30, 2016 | 9.681M |
June 30, 2016 | 0.814M |
March 31, 2016 | 226.41M |
December 31, 2015 | 227.80M |
September 30, 2015 | 234.32M |
June 30, 2015 | 341.93M |
March 31, 2015 | 116.23M |
December 31, 2014 | 115.09M |
September 30, 2014 | 108.75M |
June 30, 2014 | 68.11M |
March 31, 2014 | 68.76M |
December 31, 2013 | 68.45M |
September 30, 2013 | 78.54M |
June 30, 2013 | 36.38M |
March 31, 2013 | 45.48M |
December 31, 2012 | 45.42M |
September 30, 2012 | 35.28M |
June 30, 2012 | 9.624M |
March 31, 2012 | -0.063M |
December 31, 2011 | -0.05M |
September 30, 2011 | -0.035M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
21.02M
Minimum
Jun 2022
824.43M
Maximum
Jun 2023
426.73M
Average
284.36M
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
NeuroMetrix Inc | 2.325M |
Intra-Cellular Therapies Inc | 17.81M |
Rhythm Pharmaceuticals Inc | 74.37M |
Amylyx Pharmaceuticals Inc | 3.543M |
AN2 Therapeutics Inc | 84.99M |